DH001
/ Mengyang Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 23, 2023
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
(clinicaltrials.gov)
- P2 | N=90 | Recruiting | Sponsor: Monyan Pharmaceutical (Shanghai) Co., Ltd.
New P2 trial • Atrial Fibrillation • Breast Cancer • Cardiomyopathy • Cardiovascular • Heart Failure • Oncology
1 to 1
Of
1
Go to page
1